Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.
Experimental and clinical studies with angiotensin-converting enzyme (ACE) inhibitors have suggested that these agents may reduce the risk of atherothrombotic events. Recent studies have identified the role of angiotensin II and ACE in the regulation of fibrinolysis. There is now substantial evidence that the renin-angiotensin system (RAS) plays an important role in the regulation of vascular fibrinolytic balance. This recently recognized relationship may contribute to the vasculoprotective effects of ACE inhibitors.
Vaughan
D E
DE
Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007703:Peptidyl-Dipeptidase A / Q000187:drug effects / Q000502:physiology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control
D000806:Angiotensin-Converting Enzyme Inhibitors; D007703:Peptidyl-Dipeptidase A